Dwayne Andree Wilson
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Keybanc Raises Sterling Infrastructure Price Target to $755. Keybanc maintained an Overweight rating on Sterling Infrastructure and raised its price target to $755. This analyst action provides context as the stock trades significantly below its 52-week high of $1,005.68. The move follows recent earnings reports and a scheduled Q3 release, highlighting continued analyst interest despite the stock's recent decline.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
DT Midstream Highlights Sustainability, Data Centre Growth. DT Midstream released its annual sustainability report, outlining progress in environmental goals. The company also spoke at a utilities and clean‑energy conference, sharing insights on its midstream strategy. Additionally, it reported a jump in demand from key data‑centre markets, supporting its growth outlook.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
UBS Cuts Crown Holdings Price Target to $116. UBS has lowered its price target for Crown Holdings to $116 while maintaining a Neutral rating. This new target is below the current support level of $118.66, suggesting potential downside pressure. The move stands out as the new target is significantly lower than the average analyst estimate of $136.57.
Transaction History
| INGR | ▲ Buy | Grant | 1,797 | $193K | 5/20/2026 | View on chart |
| STRL | ▲ Buy | Grant | 181 | $0 | 5/7/2026 | View on chart |
| INGR | ▲ Buy | Grant | 380 | $43K | 3/31/2026 | View on chart |
| STRL | ▼ Sell | Open Market | 1,260 | $511K | 3/12/2026 | View on chart |
| STRL | ▼ Sell | Open Market | 1,200 | $495K | 3/5/2026 | View on chart |
| STRL | ▼ Sell | Open Market | 2,860 | $1.0M | 1/16/2026 | View on chart |
| INGR | ▲ Buy | Grant | 371 | $40K | 12/5/2025 | View on chart |
| INGR | ▲ Buy | Grant | 321 | $40K | 9/30/2025 | View on chart |
| DTM | ▲ Buy | Option Exercise | 1,443 | — | 8/2/2025 | View on chart |
| INGR | ▲ Buy | Grant | 291 | $40K | 6/30/2025 | View on chart |
| STRL | ▲ Buy | Grant | 751 | $0 | 5/8/2025 | View on chart |
| INGR | ▲ Buy | Grant | 302 | $40K | 3/31/2025 | View on chart |
| INGR | ▲ Buy | Grant | 275 | $40K | 12/12/2024 | View on chart |
| INGR | ▲ Buy | Grant | 295 | $40K | 9/30/2024 | View on chart |
| DTM | ▲ Buy | Option Exercise | 699 | — | 8/2/2024 | View on chart |
| INGR | ▲ Buy | Grant | 347 | $40K | 6/28/2024 | View on chart |
| STRL | ▲ Buy | Grant | 1,074 | $0 | 5/9/2024 | View on chart |
| INGR | ▲ Buy | Grant | 342 | $40K | 3/29/2024 | View on chart |
| CCK | ▲ Buy | Grant | 536 | $40K | 2/14/2024 | View on chart |
| INGR | ▲ Buy | Grant | 361 | $38K | 12/11/2023 | View on chart |
| CCK | ▲ Buy | Grant | 499 | $40K | 11/1/2023 | View on chart |
| INGR | ▲ Buy | Grant | 377 | $37K | 9/29/2023 | View on chart |
| CCK | ▲ Buy | Grant | 428 | $40K | 8/2/2023 | View on chart |
| DTM | ▲ Buy | Option Exercise | 666 | — | 8/2/2023 | View on chart |
| INGR | ▲ Buy | Grant | 354 | $38K | 6/30/2023 | View on chart |
| CCK | ▲ Buy | Grant | 475 | $40K | 5/3/2023 | View on chart |
| STRL | ▲ Buy | Grant | 3,353 | $135K | 5/3/2023 | View on chart |
| INGR | ▲ Buy | Grant | 381 | $37K | 3/31/2023 | View on chart |
| CCK | ▲ Buy | Grant | 465 | $40K | 2/16/2023 | View on chart |
| CCK | ▲ Buy | Grant | 583 | $40K | 11/2/2022 | View on chart |
| INGR | ▲ Buy | Grant | 450 | $37K | 10/3/2022 | View on chart |
| CCK | ▲ Buy | Grant | 413 | $40K | 7/29/2022 | View on chart |
| INGR | ▲ Buy | Grant | 422 | $37K | 7/1/2022 | View on chart |
| CCK | ▲ Buy | Grant | 363 | $40K | 5/4/2022 | View on chart |
| STRL | ▲ Buy | Grant | 4,269 | $0 | 5/4/2022 | View on chart |
| INGR | ▲ Buy | Grant | 438 | $37K | 4/1/2022 | View on chart |
| CCK | ▲ Buy | Grant | 336 | $40K | 2/17/2022 | View on chart |
| INGR | ▲ Buy | Grant | 391 | $38K | 1/3/2022 | View on chart |
| CCK | ▲ Buy | Grant | 348 | $36K | 11/3/2021 | View on chart |
| INGR | ▲ Buy | Grant | 359 | $32K | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Ingredion Sees Rising Clean-Label Demand, UBS Lowers Target
Demand for clean‑label ingredients is growing, which has helped lift Ingredion’s share price. UBS kept a neutral stance but cut its price target to $104, citing uncertainty about future momentum. The company’s T&HS solutions are being examined for their ability to sustain growth into 2026.
Ingredion Sees Rising Clean-Label Demand, UBS Lowers Target. Demand for clean‑label ingredients is growing, which has helped lift Ingredion’s share price. UBS kept a neutral stance but cut its price target to $104, citing uncertainty about future momentum. The company’s T&HS solutions are being examined for their ability to sustain growth into 2026.